X0708 D LIVE 0001541157 Akari Therapeutics Plc 75/76 WIMPOLE STREET LONDON X0 UNITED KINGDOM W1G 9RT +44 20 8004 0270 UNITED KINGDOM None Celsus Therapeutics Plc. Morria Biopharmaceuticals PLC Corporation true Clive Richardson c/o Akari Therapeutics, PLC 75/76 Wimpole Street London X0 UNITED KINGDOM W1G 9RT Executive Officer Director Dov Elefant c/o Akari Therapeutics, PLC 75/76 Wimpole Street London X0 UNITED KINGDOM W1G 9RT Executive Officer Director Ray Prudo c/o Akari Therapeutics, PLC 75/76 Wimpole Street London X0 UNITED KINGDOM W1G 9RT Executive Officer Director James Hill c/o Akari Therapeutics, PLC 75/76 Wimpole Street London X0 UNITED KINGDOM W1G 9RT Director Stuart Ungar c/o Akari Therapeutics, PLC 75/76 Wimpole Street London X0 UNITED KINGDOM W1G 9RT Director David Byrne c/o Akari Therapeutics, PLC 75/76 Wimpole Street London X0 UNITED KINGDOM W1G 9RT Director Donald Williams c/o Akari Therapeutics, PLC 75/76 Wimpole Street London X0 UNITED KINGDOM W1G 9RT Director Michael Grissinger c/o Akari Therapeutics, PLC 75/76 Wimpole Street London X0 UNITED KINGDOM W1G 9RT Director Peter Feldschreiber c/o Akari Therapeutics, PLC 75/76 Wimpole Street London X0 UNITED KINGDOM W1G 9RT Director Biotechnology Decline to Disclose 06b false 2019-06-28 false true true false 0 Paulson Investment Company, LLC 5670 None None 2141 W. NORTH AVE. 2ND FLOOR CHICAGO IL ILLINOIS 60647 AL ALABAMA AZ ARIZONA CA CALIFORNIA CO COLORADO CT CONNECTICUT FL FLORIDA IL ILLINOIS KS KANSAS MD MARYLAND MA MASSACHUSETTS MI MICHIGAN MN MINNESOTA NV NEVADA NH NEW HAMPSHIRE NJ NEW JERSEY NM NEW MEXICO NY NEW YORK OH OHIO PA PENNSYLVANIA TX TEXAS VA VIRGINIA WA WASHINGTON true 4499945 4499945 0 The warrants and shares underlying the warrants, the subject matter of this Form D were issued in connection with an offering of (i) 2,368,392 ADSs issued in a registered direct offering, and (ii) unregistered warrants to purchase 1,184,213 ADSs. false 45 337496 0 Paulson Investment Company, LLC is also entitled to expense reimbursement of up to $50,000, a non-accountable expense allowance of $10,000 and warrants to purchase an aggregate of 177,629 ADSs exercisable at $2.85 per ADS for five years. 0 Issuer expects to use proceeds from the offering to fund its ongoing research and clinical development efforts and for working capital and general corporate purposes. false Akari Therapeutics Plc /s/ Clive Richardson Clive Richardson Interim Chief Executive Officer and Chief Operating Officer 2019-07-12